Ensuring that health professionals caring for
the youngest patients have access to advanced wound care and
infection prevention solutions
Visit Covalon at booth 307 at the 46th Annual
APHON Conference & Exhibit in West
Palm Beach on September 15 –
17, 2022
MISSISSAUGA, ON, Sept. 13,
2022 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical
technologies company, is pleased to announce its participation in
the 46th Annual Association of Pediatric Hematology/Oncology Nurses
(APHON) Conference & Exhibit at the Palm Beach County Convention Center in
West Palm Beach, Florida on
September 15 – 17, 2022. Visit
Covalon at booth 307 to learn how our infection prevention and
advanced wound care products are making a difference in the lives
of our youngest patients.
With more than 25 leading children's hospitals currently using
or evaluating Covalon's VALGuard product, the world's only
FDA-approved vascular access line guard, the need to find a
solution to help protect line-to-line connections to reduce central
line associated bloodstream infections ("CLABSIs") has never been
greater. Bloodstream infections are up 65% in intensive
care units, and there is an urgent need to adopt new compassionate
care technologies in the fight to protect patients.
"Effective infection prevention strategies require the best
products targeted at the contributors to the risk of infection,"
started Brian Pedlar, CEO of
Covalon. "With studies indicating up to 71% of
catheter-related infections being linked to catheter hub
contamination – Covalon's VALGuard product was developed to help
prevent these infections. I encourage all attendees at APHON
to see what's new at Covalon's booth."
The Conference provides premier educational content, networking,
and social events for nurses specializing in pediatric
hematology/oncology. Covalon will be hosting an exhibit
throughout the conference dates. Visit us at booth 307 to
learn how our infection prevention and advanced wound care products
are making a difference in the lives of our youngest patients.
To register for the conference, please visit
https://conference.aphon.org. To book an appointment with a
Covalon representative, please email Ron
Hebert, SVP Marketing, Covalon Technologies Ltd., at
rhebert@covalon.com.
Covalon's patented products include:
- VALGuard® - an FDA-approved, transparent, environmental barrier
designed to protect catheter hubs and line connections from
external contaminants and gross contamination, including body
fluids and other secretions. It incorporates a quick-release pull
strip for fast access to infusion hubs and for easy removal.
- SurgiClear® - a transparent, breathable, fluid impermeable
barrier that isolates the wound site from external contamination
while providing dual antimicrobial protection throughout the entire
surface of the dressing. It uses a low but effective concentration
of chlorhexidine and silver embedded into an atraumatic silicone
adhesive that covers the entire transparent surface area to allow
for easy and consistent monitoring of wound sites.
- IV Clear® - a vascular access dressing that offers complete
transparency at and around the insertion site for easy daily
assessment. It uses a soft silicone adhesive to preserve the skin's
barrier function and minimize skin injuries and incorporates safe
amounts of antimicrobials, without sacrificing efficacy, to protect
against chemical irritation.
About Covalon
Covalon Technologies Ltd. is a researcher, developer,
manufacturer, and marketer of patent-protected medical products
that improve patient outcomes and save lives in the areas of
advanced wound care, infection management and surgical procedures.
Covalon leverages its patented medical technology platforms and
expertise in two ways: (i) by developing products that are sold
under Covalon's name; and (ii) by developing and commercializing
medical products for other medical companies under development and
license contracts. The Company is listed on the TSX Venture
Exchange, having the symbol COV and trades on the OTQX Market under
the symbol CVALF. To learn more about Covalon, visit our website at
www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" or variations of such words and
phrases or state that certain actions, events or results "may",
"could", "would", "might", "will" or "will be taken", "occur" or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
three and nine months ended June 30,
2022, which is available on the Company's profile at
www.sedar.com, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Investors should not
place undue reliance on any forward-looking statements. The
forward-looking statements contained in this news release are made
as of the date of this news release, and the Company assumes no
obligation to update or alter any forward-looking statements,
whether as a result of new information, further events or
otherwise, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-to-introduce-new-infection-prevention-products-at-the-annual-association-of-pediatric-hematologyoncology-nurses-aphon-conference-301623205.html
SOURCE Covalon Technologies Ltd.